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Abstract It has been suggested that a-dystroglycan links the 
dystrophin-associated protein complex and extracellular matrix 
and that the absence of dystrophin and a-dystroglycan in 
Duchenne muscular dystrophy (DMD) may lead to the break-
down of this linkage. In the present study, myotubes from D M D 
patients and murine X-linked muscular dystrophic mice (mdx) 
were used to measure their adhesive force to the physiological 
laminin-(x2 substrate, and it was found that the dystrophic 
myotubes were selectively unable to sustain adhesion. However, 
normal and dystrophic myotubes attached equally well to the 
laminin-al substrate. As far as we know, this is the first 
experimental evidence that the absence of dystrophin causes the 
complete loss of a still unknown laminin-a2-dependent adhesion 
force, therefore suggesting that the primary consequence of 
Duchenne dystrophy consists of the loss of an authentic 
mechanical linkage at the level of the a-dystroglycan/basal 
lamina interface. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Dystrophin is missing in Duchenne dystrophy and the dys-
trophin-associated protein (DAP) complex is either poorly ex-
pressed or totally absent. Sarcoglycans and dystroglycans are 
major components of the D A P complex, and a number of 
diseases are due to mutat ions in the former [1,2]. In muscle, 
the D A P complex appears to play two important roles: it is 
involved in the stabilisation of the acetylcholine receptor 
(AChR) clusters linking agrin and utrophin [3] and it binds 
merosin, one of the most important proteins of the extracel-
lular matrix (ECM), to the sarcolemma. Both of these func-
tions are achieved by α-dystroglycan (previously known as 
cranin [4,5]), a 156-kDa protein expressed in muscle, brain 
and other tissues that binds in a Ca 2 + -dependent manner to 
the distal end of the a-chain of laminin via the last two glob-
ular repeats [6]. 
Although it has been hypothesised on structural grounds 
[1,2] that D A P is the major mechanism of at tachment between 
the cytoskeleton and ECM in skeletal muscle, there are no 
demonstrations of its quantity or functional role. 
In the present paper, we provide evidence (with quantitative 
measurements [7]) that the forces sustaining the adhesion of 
D M D and mdx myotubes to laminin-a2 are several times less 
strong than those of normal myotubes, thus supporting the 
notion that the lack of α-dystroglycan has dramatic conse-
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quences on the machinery sustaining adhesion. Moreover, 
our results highlight the mechanical role of a-dystroglycan 
when it binds to merosin in E C M and thus links the cytoskel-
eton to E C M in normal muscle cells. 
2. Materials and methods 
2.1. Culture 
2.1.1. Mouse. The myotubes were prepared from the limb muscles 
of 3^1-day-old normal (C57BL/10ScSn) and mdx (C57BL/MDX) mice 
following procedures previously described [8]. Briefly, the explants of 
muscle tissue were plated in 80% HAM F-10 culture media (Sigma), 
20% fetal calf serum (FCS, Hyclone, The Netherlands), 2 mM gluta-
mine, 2.5 ng/ml basic fibroblast grown factor (FGF, F-0291, Sigma, 
Italy) for normal and 0.5 ng/ml for mdx myoblasts [9]. In this pro-
liferative medium, myoblasts and satellite cells spread out in 3 days. 
On the third day, they were replated in a differentiative medium of 
98% DMEM (Hyclone) and 2% horse serum (HS), in which the 
mononucleated muscle cells initiated a terminal differentiation consist-
ing of cellular fusion and myotube maturation. The myotubes were 
mechanically detached and resuspended in DMEM, 250 μg/ml bovine 
serum albumine (BSA), 1.74 mM EGTA (external Ca2+ was reduced 
in order to decrease Ca2+ influx and prevent contraction), and then 
plated on laminin-al (Collaborative Research, USA, 2 μ^τηΐ) or -o¡2 
(Chemicon, USA, 5 μg/ml) -coated dishes previously saturated with 
250 μg/ml BSA (Sigma, Italy). After 12-24 h, the dishes were used for 
adhesion experiments. 
2.1.2. Human. Primary myoblasts were obtained from muscle bi-
opsies of three DMD patients and three age-matched normal controls 
following procedures previously described [10]. The DMD patients 
had the clinical and pathological features characteristic of DMD, 
and the absence of dystrophin was assessed in their muscle by means 
of imrnunohistochemistry as previously described [11]. The normal 
controls were individuals who had undergone muscle biopsy for diag-
nostic purposes but were found to be free of muscle disease. Briefly, 
the muscle samples were freed of fat and connective tissue, minced to 
obtain fragments that were smaller than 1 mm3, and then dissociated 
by means of two or three successive treatments with trypsin-EDTA. 
After dissociation, the cells were washed, resuspended in culture me-
dium (see below), plated in culture dishes and grown to 70% conflu-
ence. In order to eliminate fibroblast contamination, the cells were 
harvested by means of trypsin treatment, washed, incubated with 
Texas red-conjugated anti-CD56 monoclonal antibody (Becton-Dick-
inson, San Jose, CA) and sorted using a fluorescence-activated cell 
sorter (FacStar Plus, Becton-Dickinson) according to the procedure 
described by Webster et al. [10]. The myoblasts were plated in 60 mm 
petri dishes and maintained at 37°C and 5% CO2 in the following 
medium: DMEM (Gibco, Gaithersburg, MD) containing 20% FCS 
(Hyclone, Logan, UT), 10 ng/ml epidermal growth factor (EGF, Gib-
co) and 10 μg/ml bovine insulin (Sigma, St. Louis, MO). In order to 
obtain myotube cultures, the myoblasts were plated in 35 mm lam-
inin-al or -a2-coated dishes and allowed to fuse (4-5 days) into 
multinucleated myotubes by replacing the growth medium with a 
fusion medium containing 2% FCS without mitogens. 
2.2. Quantitative measurements of adhesion 
2.2.1. Procedure. In order to determine precisely the force exerted 
by the binding of ECM to its receptors, we developed a quantitative 
method of measurement. Briefly, Petri dishes with primary cultures of 
mouse myotubes were placed in suitable positions in classical centri-
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fuges (Labofuge M, Hereus) in order to apply forces (proportional to 
the amount of acceleration and the mass of the myotube) that were 
perpendicular to the plating surface and break cell adhesion. By vary-
ing the speed of the centrifuge during predetermined periods of times 
(1.5-2 min), the forces could be applied in a reproducible manner. 
Videotape recording set-up was used to store 144 1X 1 mm images, 
for each petri dish, before and after centrifugation. Using two screens 
the number of myotubes of corresponding images was counted and we 
derived the percentage of myotubes remaining attached in the same 
petri dish (% adhesion, mean ± SEM) before and after the application 
of increasing forces. The Petri dishes were used only once and, after 
the treatment, the attached cells were still in perfect physiological 
condition (normal resting potential and contractility, not shown). 
Briefly, the rationale underlying the procedure is as follows. The 
adhesive force (F&) is proportional to specific adhesion (a) multiplied 
by the adhesion area, which is approximately proportional to the 
product of myotube length (!) and diameter (2r), giving F&-aXlx2r. 
The centrifugal force (Fc) is proportional to the product of acceler-
ation (a) and mass, which is proportional to the myotube length and 
cross-sectional area (w2) giving Fc = aXlXnr
2. A cell detaches when 
Fc > F&, and so, if all other conditions are equal, the larger myotubes 
(larger r) detach first. In particular, we expect that % adhesion (as a 
function of centrifugal acceleration) should follow a sigmoidal curve 
(see dotted line, Fig. 1, right) that is more or less steep according to 
the variability in the myotube population: steep for an almost uni-
form population and less steep for myotubes of very different dimen-
sions. Under these conditions, the half-way point of the curves also 
becomes a reasonable absolute measure of adhesion force. From our 
data, we can calculate that the force sustained by a typical myotube 
(100 μιη long, 10 μιη wide and 2 μιη thick) before becoming detached 
is roughly 4 x l 0 - 5 dyne, a value that corresponds to a force per 
surface area of about 4 dyne/cm2, which is in good agreement with 
the data reported in the literature [12]. 
2.3. Test and control experiments 
The sensitivity of the method was tested under experimental con-
ditions in which the substrata and extracellular media were changed. 
The plot of the % adhesion of control murine myotubes to varying 
concentrations of laminin-al is shown in Fig. 1 (left) at one single 
force (corresponding to an imposed acceleration of 50 g). In order to 
gain insight into the detection limits of the method we investigated the 
effect of different concentrations of substrate to varying forces as 
shown in Fig. 1 (middle), where it is possible to see that the complete 
removal of the attachment of the myotubes is clearly described at a 
concentration of 2 μg/ml but not 10 μg/ml of laminin-al. On the 
whole, the results of these experiments indicated that, in order to 
show a correct description of the detachment and to minimize the 
possibility of cell damage [13,14], we should reduce the force required 
to detach the cells. Accordingly, we decided to decrease the concen-
tration of substrate to 2 μg/ml in all the successive experiments. This 
is in agreement with the fact that it is known that a-dystroglycan 
binds laminin with affinities substantially higher than laminin recep-
tors of the integrin superfamily [6]. 
In order to verify whether the method was sensitive enough to 
detect different origins of the adhesion process, we performed experi-
ments in two different extracellular media (Hanks' balanced salt sol-
ution, with Ca2+ and without Mg2+ or vice versa), which should 
qualitatively correspond to a-dystroglycan-dependent [6] and integ-
rin-dependent adhesion [15-17], respectively. The results of these ex-
periments are shown in Fig. 1 (right), in which it is possible to see 
that, in laminin-al, myotubes adhere more strongly under +Mg2+/ 
—Ca2+ (Fig. 1, T ) conditions than in —Mg2+/+Ca2+ conditions 
(Fig. 1, A ) ; in the case of laminin-a2 (5 μg/ml; Fig. 1, Δ , ν ) the 
differences in adhesion do not appear to be significant. On the whole, 
the results of these control experiments suggest that the procedure for 
evaluating adhesion is sensitive enough to distinguish the various 
types of substrata and conditions that mediate the strength of the 
mechanical adhesion of myotubes to physiological substrata. All of 
the data presented in the Results section were obtained under —Mg2+/ 
+Ca2+ conditions. 
2.4. Immunofluorescence of DMD myotubes 
For each patient, myotube-containing petri dishes were stained in 
order to detect any dystrophin-positive myotubes formed from revert-
ant nuclei. The cells were fixed in methanol and dystrophin was 
localised by means of a polyclonal antibody directed against the fu-
sion peptide located at the C-terminus of the protein using a biotin-
avidin system [18]. In the same dish, 4',6-diamidino-2-phenylindole 
(DAPI) was used to mark nuclei. Percentage counts of the myotubes 
( ~ 200/dish) showed that an average of only 6% of the total number 
of myotubes were dystrophin-positive. 
3. Results 
3.1. Myotubes from normal and 'mdx' mice adhere to 
laminin-al equally well 
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Fig. 1. Characterisation of the methodology (mouse myotubes). Left: Plot of % adhesion (n = 4) at a fixed force (calibrated in acceleration, 
g units) of mouse myotubes as a function of laminin a l concentration. Middle: % Adhesion (n = 4) as a function of the perpendicular force ap-
plied to the petri dish at two different laminin-al concentrations of 10 (o) and 2 ( · ) μg/ml, respectively. Right: Effects of media with different 
divalent cations. The data derive from experiments using laminin-al ( A , T ) or laminin-a2 ( Δ , ν ) , and in the presence of Mg2+ without Ca2+ 
( v , r ) or in the presence of Ca2+ without Mg2+ ( Δ , Α ) ; see Section 2. Each point is the mean of four different experiments. The dashed line 
is the sigmoidal curve which best fitted the experimental points ( τ ) . The average number of counted cells/petri dish (experiment) was 320±21. 
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Fig. 2. Laminin-ccl-mediated adhesion of control and mdx mouse 
myotubes. Upper panel: Experiments using normal myotubes (D) 
and an integrin subunit βι antibody (o, see Section 3.1). Lower 
panel: Experiments using mdx myotubes. Each point is the average 
of five experiments; the average number of cells/petri was 472 ±30. 
assess the adhesion of the mdx myotubes, as shown in Fig. 2. 
The experiments were performed using both normal (Fig. 2, 
upper panel) and mdx (Fig. 2, lower panel) mouse myotubes. 
It is clear that the mdx and control myotubes adhere in a 
similar manner thus suggesting that the major mechanisms 
sustaining the adhesion to laminin-al may be different from 
the supposed oc-dystroglycan-mediated link. The use of an 
antibody raised against the ßi-subunit [19] of mouse integrin 
severely impaired any type of adhesion on laminin-al (Fig. 2, 
upper, o ) . 
3.2. 'mdx' but not normal myotubes are unable to adhere to 
laminin-a2 
The results of the similar experiments performed using 1am-
inin-a2 are shown in Fig. 3 (left). Under control conditions 
the degree of adhesion was remarkably high at a laminin-a2 
concentration of 5 μ^ητΐ, but the experiment involving mdx 
myotubes showed very poor adhesion: at 75 g, the normal 
myotubes showed 95% adhesion as against the 5% adhesion 
of mdx myotubes. On the whole, these results suggest that 
laminin-a2 selectively reveals a striking difference in the level 
of the adhesion force used by normal and mdx myotubes to 
contact ECM. 
3.3. DMD myotubes are also unable to adhere to laminin-a2 
whereas normal myotubes are almost undetachable. 
We used human normal and DMD myotubes to repeat the 
mouse experiments described above. As shown in Fig. 3 
(right), the results were qualitatively very similar. Given that 
formed human myotubes are particularly large and delicate, 
we had to culture myoblasts directly on laminin-oe2 sub-
strates; this led to such strong adhesion that it was almost 
impossible to detach the myotubes even at very high forces. 
Although the myotubes in the DMD cultures were somewhat 
smaller and thus less inclined to be detached (see Section 2), 
we found the same interesting difference as that shown for 
mouse: the DMD cells detached at a force that was several 
times less than that necessary to detach normal cells. Control 
experiments (not shown) with human myotubes on substrata 
coated with laminin-al showed a 50% adhesion at 600 g for 
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Fig. 3. Adhesion of normal and mdx mouse myotubes (left) and human DMD myotubes (right) to laminin-a2 substrata. Left panel: Notice 
that the mdx myotubes adhered to the laminin-a2 substratum much less strongly than the normal myotubes. Each point is the mean of four 
experiments; the average number of cells/petri was 610 ±24. Right panel: Note that DMD myotubes can be detached at forces at which normal 
myotubes are virtually undetectable. Each point is the mean of three experiments; the average number of cells/petri was 900 ±42. 
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result that is in keeping with our previous observations, sug-
gesting that laminin-al is incapable of recognizing the differ-
ence between normal and DMD muscle cells. 
On the whole, the results on human myotubes were in com-
plete agreement with those observed in mouse, and suggest 
that the inability to adhere strongly to laminin-oc2 is peculiar 
to Duchenne and mdx diseases, in which myocells are known 
to lack dystrophin and a-dystroglycan. 
4. Discussion 
The results reported in the present paper demonstrate that 
dystrophic myotubes (from mdx mice and DMD patients), 
which are known to lack α-dystroglycan, are incapable of 
correctly contacting laminin-a2 although they do correctly 
adhere to normal laminin-al. 
It has recently been shown that laminin-a2 and not lami-
nin-al are expressed in 14—17-day-old mouse embryos at the 
level of the muscle fibre basement membranes. Moreover, my-
oblasts can spread much faster on laminin-a2 than -ccl, thus 
suggesting that the functional roles of the two forms may be 
quite different [20]. Furthermore, a number of studies [21-23] 
suggest the presence of integrins αγβι in myotubes although 
no conclusions can yet be drawn as to whether the same in-
tegrin also mediates binding to laminin-a2 [24]. We found 
that laminin-al perfectly supports the adhesion of mdx my-
otubes lacking α-dystroglycan: the obvious conclusion is that 
this type of adhesion is sustained by other receptors (puta-
tively αγβι) and that the possible disorganisation of the mdx 
membrane and cytoskeleton does not affect these receptors. It 
has previously been shown [25] that mdx are more fragile than 
normal myotubes, but our data indirectly indicate that this 
fragility is restricted to the level of the cytoskeleton, and 
does not involve the sarcolemma/ECM interface, which func-
tions normally when laminin is present. It is becoming in-
creasingly clear that muscular dystrophy may be caused by 
mutations in a number of the proteins involved in the stabil-
isation of muscle cell membrane, including the attachment of 
cell to the ECM. In this respect, some human (congenital 
muscular dystrophy, CMD and Fukuyama-type congenital 
muscular dystrophy, FCMD) and mouse (dy) muscular dys-
trophies have been shown: (i) to depend on the deficiency or 
incorrect functioning of laminin-a2 which binds a-dystrogly-
can [26,27] and (ii) to cause muscle weakness similar to Duch-
enne and Becker dystrophies. On the whole, our results sug-
gest that the DMD defect, (which is specular to that of CMD) 
may have the direct consequence of impairing the assembly of 
muscle fibers in a complicated and still unclear manner. 
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